News Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 17, 2020- Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D. and Paul J. Utz, M.D. -
-
Nov 5, 2020- Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 -
-
Nov 2, 2020- Top-Line Data Expected in Q1 2021 -
-
Oct 20, 2020- European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic's lead asset, IMU-838, in moderate COVID-19
-
Sep 11, 2020- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -